Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASKA Pharmaceutical Holdings Co Ltd stock PB Ratio (=0.82) is close to 3-year low of 0.8.
The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's PB Ratio or its related term are showing as below:
TSE:4886'
s PB Ratio Range Over the Past 10 Years
Min: 0.55 Med: 0.88 Max: 1.21
Current: 0.82
During the past 5 years, ASKA Pharmaceutical Holdings Co's highest PB Ratio was 1.21. The lowest was 0.55. And the median was 0.88.
TSE:4886's PB Ratio is ranked better than 83.15% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs TSE:4886: 0.82
During the past 12 months, ASKA Pharmaceutical Holdings Co's average Book Value Per Share Growth Rate was 7.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.70% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of ASKA Pharmaceutical Holdings Co was 9.90% per year. The lowest was 8.70% per year. And the median was 9.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ASKA Pharmaceutical Holdings Co PB Ratio Related Terms
ASKA Pharmaceutical Holdings Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASKA Pharmaceutical Holdings Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where ASKA Pharmaceutical Holdings Co's PB Ratio falls into.
ASKA Pharmaceutical Holdings Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ASKA Pharmaceutical Holdings Co (TSE:4886) has a PB Ratio of 0.82 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. This is near median its historical median of 0.88. Over the past decade, ASKA Pharmaceutical Holdings Co's PB Ratio has ranged from 0.55 to 1.21. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #155 out of 920 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is ASKA Pharmaceutical Holdings Co's PB Ratio too high?
ASKA Pharmaceutical Holdings Co's current PB Ratio of 0.82 is near median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 1.21. The Drug Manufacturers industry median PB Ratio is 1.98. ASKA Pharmaceutical Holdings Co's value of 0.82 is 58.6% below this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #155 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #155 out of 920 companies for PB Ratio. This places ASKA Pharmaceutical Holdings Co in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.98. ASKA Pharmaceutical Holdings Co's value of 0.82 is 58.6% below this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own PB Ratio has ranged from 0.55 to 1.21 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 1.98, ASKA Pharmaceutical Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current PB Ratio of 0.82 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ASKA Pharmaceutical Holdings Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current PB Ratio is 0.82, which is near median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,429.06, compared to a current price of 円2,035.00 — trading 16.2% below its estimated fair value. The current PB Ratio is 0.82, which is near median its 10-year median of 0.88 and 58.6% below the Drug Manufacturers industry median of 1.98. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current PB Ratio is 0.82 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,035.00 is trading 16.2% below its estimated GF Value™ of 円2,429.06.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Modestly Undervalued.
Key valuation signals for TSE:4886:
PB Ratio: 0.82 (near median its 10-year median of 0.88)
GF Value™: 円2,429.06 vs. price of 円2,035.00 (16.2% below fair value)
Industry Position: 58.6% below the Drug Manufacturers median (#155 of 920)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
59GF Score
Get the complete analysis for TSE:4886
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
